Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (TRISTAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03468296
Recruitment Status : Not yet recruiting
First Posted : March 16, 2018
Last Update Posted : April 20, 2018
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Tennessee Retina

Brief Summary:
This study is designed to evaluate the safety and efficacy of every 2 week intravitreal aflibercept injections in a population of neovascular AMD patients that have demonstrated refractory subretinal fluid with or without intraretinal fluid despite prior monthly intravitreal aflibercept treatment.

Condition or disease Intervention/treatment Phase
Neovascular Age-related Macular Degeneration Drug: Intravitreal Aflibercept Injection 2mg Phase 4

Detailed Description:

Eligible patients will be scheduled to receive intravitreal aflibercept (2.0mg) injections for six consecutive 2 week (13-15 days) intervals with injections administered at weeks 0, 2, 4, 6, 8, 10, and 12. The primary endpoint visit to assess response to sustained q2week therapy will be at the week 14 visit. No treatment will be administered at this visit. All patients will then return at week 16 for the randomization visit and receive a repeat intravitreal aflibercept (2.0mg) injection. For purposes of randomization, patients will be separated into the following groups:

  • Q2 week complete responders: absence of subretinal fluid on OCT at week 16
  • Q2 week incomplete responders: persistent subretinal fluid on OCT at week 16

The "q2 week complete responders" will subsequently be transitioned to a treat and extend regimen with a minimum inter-treatment interval of 4 weeks through week 24. The "q2 week incomplete responders" will be randomized in a 1:1 fashion into one of two arms:

  • Continued q2 week treatment: intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
  • Transition to treat-and-extend treatment: through week 24 with a minimum inter-treatment interval of q4 weeks. This arm is identical to regimen for "q2 week complete responders."

Beginning in week 24, all patients (all groups) will undergo treatment delivered on a treat-and-extend basis with a minimum inter-treatment interval of 4 weeks through the week 50. Patient visits will be treated no more frequent than q4 weeks during treat-and-extend portions of the protocol.

All patients will have a mandatory study termination visit at week 52 (-1/+2 weeks). No study treatment will be administered after week 50. Patients receiving a study treatment after week 48 will return 4 weeks after this final study treatment for study termination visit. Patients receiving a study treatment at or before week 48 in whom the treat-and-extend protocol would dictate a subsequent visit after week 52 will instead return at week 52 for a study termination visit.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
Estimated Study Start Date : April 2018
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Continued Q2 Week Treatment
Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
Drug: Intravitreal Aflibercept Injection 2mg
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
Other Name: Aflibercept; EYLEA®; VEGF Trap-Eye

Active Comparator: Treat-And-Extend Treatment
Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
Drug: Intravitreal Aflibercept Injection 2mg
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
Other Name: Aflibercept; EYLEA®; VEGF Trap-Eye




Primary Outcome Measures :
  1. Adverse Events [ Time Frame: Through Week 14 ]
    Frequency and severity of ocular and systemic adverse events


Secondary Outcome Measures :
  1. Retinal Thickness [ Time Frame: Weeks 14, 16, 24, 52 ]
    Central Subfield Thickness on Optical Coherence Tomography

  2. Subretinal Fluid Height [ Time Frame: Weeks 14, 16, 24, 52 ]
    Max subretinal fluid height week on Optical Coherence Tomography

  3. Pigment Epithelial Detachment Height [ Time Frame: Weeks 14, 16, 24, 52 ]
    Max pigment epithelial detachment height on Optical Coherence Tomography

  4. Proportion of Dry Maculas [ Time Frame: Weeks 14, 16, 24, 52 ]
    Proportion of eyes with a dry macula (no subretinal fluid on Optical Coherence Tomography)

  5. Best-Corrected Visual Acuity [ Time Frame: Weeks 14, 24, and 52 ]
    Mean best-corrected visual acuity

  6. Change in Best-Corrected Visual Acuity [ Time Frame: Weeks 14, 24, and 52 ]
    Mean change in best-corrected visual acuity from baseline

  7. Proportion gaining >5 letters of Best-Corrected Visual Acuity [ Time Frame: Weeks 14, 24, and 52 ]
    Proportion of eyes gaining > 5 letters

  8. Treatment Burden [ Time Frame: Through Week 52 ]
    Mean number of injections administered

  9. Ability to Extend Treatment Interval [ Time Frame: Through Week 52 ]
    Proportion of eyes able to be extended during treat-and-extend dosing



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 50 years
  • A diagnosis of choroidal neovascularization related to age-related macular degeneration
  • ETDRS refracted BCVA ≥ 20/200
  • Prior treatment with any anti-VEGF agent for ≥ 12 months
  • Prior treatment with at least five intravitreal aflibercept at the time of screening (week -2) with an average inter-treatment interval <35 days
  • Presence of persistent subretinal fluid with or without intraretinal fluid on OCT at most recent standard of care visit occurring 28-35 days following most recent intravitreal aflibercept injection
  • Demonstration of definite improvement in overall retinal thickness and/or subretinal fluid on OCT based on evaluation of examining investigator at screening visit (week -2) 13-15 days following most recent standard of care visit

    o Note: screening OCT will be performed prior to dilation to allow for undilated ETDRS BCVA testing following confirmation of eligibility

  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed informed consent

Ocular Exclusion Criteria:

  • Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy in the study eye
  • Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye
  • Concurrent eye disease in the study eye that could compromise visual acuity (e.g. advanced diabetic retinopathy, advanced glaucoma)
  • Active intraocular inflammation (grade trace or above) in the study eye
  • Current vitreous hemorrhage in the study eye
  • History of macula-involving rhegmatogenous retinal detachment or macular hole (Stage 2 - 4) in the study eye
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Aphakia in the study eye
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)

Systemic Exclusion Criteria

  • Use of systemic anti-VEGF medications within 6 months of screening visit
  • History of cerebrovascular accident, myocardial infarction, ventricular arrhythmia, unstable angina, coronary or peripheral artery bypass or stenting within 6 months of day 0
  • History of deep vein thrombosis or pulmonary embolus within 6 months of day 0
  • Uncontrolled hypertension (>160/100 on medical treatment)
  • Pregnant or breast-feeding women
  • Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception prior to the initial dose administration (baseline visit, week 0). Adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly.

    • Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03468296


Locations
Layout table for location information
United States, Tennessee
Tennessee Retina Not yet recruiting
Nashville, Tennessee, United States, 37203
Contact: Eric Schneider, MD    615-983-6000    eschneider@tnretina.com   
Sub-Investigator: Carl Awh, MD         
Sub-Investigator: Brandon Busbee, MD         
Sub-Investigator: Kenneth Moffat, MD         
Sub-Investigator: Peter Sonkin, MD         
Sub-Investigator: Everton L Arrindell, MD         
Sub-Investigator: Roy T Wallace, MD         
Principal Investigator: Eric Schneider, MD         
Sub-Investigator: David Reichstein, MD         
Sub-Investigator: Franco Recchia, MD         
Sponsors and Collaborators
Tennessee Retina
Regeneron Pharmaceuticals

Layout table for additonal information
Responsible Party: Tennessee Retina
ClinicalTrials.gov Identifier: NCT03468296     History of Changes
Other Study ID Numbers: VGFTe-AMD-1819
First Posted: March 16, 2018    Key Record Dates
Last Update Posted: April 20, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Tennessee Retina:
age-related macular degeneration

Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases